High dose peptichemio in pretreated neuroblastoma.

Abstract	The aim of this study was to evaluate the antitumor effect and toxicity of a single course of Peptichemio at high dose (450 mg/sq m) given to children with neuroblastoma resistant to first line treatment or at relapse. A total of 28 children were treated. Seven children showed partial response, 4 minor response, 8 had stable disease, and in 8 the tumor progressed. The principal toxic effect was myelosuppression. Hemorrhagic enteritis with liver failure and toxic death occurred in 1 patient. High dose Peptichemio can be administered with tolerable toxicity, inducing tumor regression in one third of previously treated patients.
Authors	A Garaventa, B De Bernardi, L Cordero Di Montezemolo, G Pastore, C De Laurentis, E Nardi, F Casale, A Mancini, G Loiacono
Journal	Anticancer research (Anticancer Res) 1989 Jul-Aug Vol. 9 Issue 4 Pg. 1157-60 ISSN: 0250-7005 [Print] Greece
PMID	2817797 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antineoplastic Agents Peptichemio Melphalan
Topics	Adolescent Antineoplastic Agents (therapeutic use) Blood Cell Count Child Child, Preschool Drug Resistance Female Humans Infant Male Melphalan (analogs & derivatives) Neoplasm Recurrence, Local Neuroblastoma (drug therapy) Peptichemio (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!